Adherence to riluzole therapy in patients with amyotrophic lateral sclerosis in three Italian regions-The CAESAR study.

Sabrina GiomettoMarco FinocchiettiOlga PaolettiNiccolò LombardiMaria Grazia CelaniFrancesco SciancaleporeErsilia LucenteforteUrsula Kirchmayernull null

Published in: Pharmacoepidemiology and drug safety (2023)

Most ALS patients who start riluzole adhere to therapy during the first year. Patients who discontinue therapy early show greater fragility and mortality.

Keyphrases

amyotrophic lateral sclerosis
type diabetes
metabolic syndrome
adipose tissue
risk factors
coronary artery disease
mesenchymal stem cells
skeletal muscle
cell therapy
insulin resistance